Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

Also called NCT03373461

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 112 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03373461
  • EudraCT 2017-000891-27
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Argentina, Australia, Belgium, Brazil, China, Colombia, Czechia, Denmark, Finland, France, Germany, Hong Kong SAR China, India, Israel, Japan, Malaysia, Netherlands, Norway, Singapore, South Korea, Sweden, Taiwan, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03373461. Randomized; double masking; primary purpose treatment. Start 2018-02-07 (actual); primary completion 2020-12-29 (actual). Results posted on 2022-10-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
Condition
IgA Nephropathy
Intervention (Drug)
LNP023
Intervention (Other)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct03373461
Content hash
f5d8f2d6bfa620cef63bb560143566f5a7ab7b913005229f4d62595ab776b2bf